Abstract
Cyclophosphamide (CYC) is the cornerstone of the treatment of systemic sclerosis (SSc)-associated fibrosing alveolitis (FAS). Despite treatment with CYC, in a not negligible proportion of SSc-FAS patients, deterioration in lung function can be observed. Interleukin-1 (IL-1) cluster gene single nucleotide polymorphisms (SNPs) were implicated in the pathogenesis of some interstitial lung diseases and may favor the progression of restrictive lung disease in SSc. The present retrospective case-control study was conducted on 18 SSc patients previously treated with oral CYC (2 mg/kg) and medium-dose steroids (prednisone 25 mg for 3 months and then tapered to 5 mg/day) for the presence of FAS—defined as the presence of areas of ground-glass attenuation on high-resolution computed tomography (HRCT) and a recent deterioration in lung function. The T/C substitution at position −889 of the IL-1α promoter gene (T-889C) was determined by polymerase chain reaction and restriction length fragment analysis. Patients carrying the T allele showed a significant decrease in forced vital capacity (FVC) values after 12 months of therapy (2.46±1.09 vs 2.59±1.17 l), while wild-type patients showed an increase in FVC values (2.73±0.54 vs 2.54±0.5 l) (p=0.005 between the two groups, analysis of variance for repeated measures). Patients with the T-889C polymorphism presented higher baseline erythrocyte sedimentation rates (ESR) compared to wild-type patients (50.3±25.4 vs 23.3±17.7 mm/h). Baseline ESR inversely correlated with the variation of FVC (ΔFVC) after 12 months of therapy (r=−0.50 and p<0.05). The two groups were otherwise similar with respect to autoantibodies, age, disease duration, disease subset, radiological HRCT grade, and baseline lung physiology. The T-889C polymorphism represents a marker for worse functional responses to CYC in SSc-FAS. The mechanisms by which this SNP may negatively influence the response to CYC therapy are unknown, but might be linked to increased inflammatory responses in the lungs.
References
Wells AU, Hansell DM, Corrin B, Harrison NK, Goldstraw P, Black CM et al (1992) High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax 47:738–742
Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD et al (2005) Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 52:592–600
White B, Moore WC, Wigley FM, Xiao HQ, Wise RA (2000) Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 1932:947–954
Beretta L, Caronni M, Raimondi M, Ponti A, Viscuso T, Origgi L et al (2006) Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience at one centre. Clin Rheumatol DOI:10.1007/s10067-006-0254-x
Clements P, Furst DE, Silver RM, Tashkin DP, Roth MD, Goldin J et al (2005) The Scleroderma Lung Study (SLS) shows the beneficial effects of cyclophosphamide (CYC) over placebo (PL) in systemic sclerosis (SSc) patients with active alveolitis. Arthritis Rheum 52:S624 (Suppl)
Hutyrova B, Pantelidis P, Drabek J, Zurkova M, Kolek V, Lenhart K et al (2002) Interleukin-1 gene cluster polymorphisms in sarcoidosis and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 165:148–151
Yucesoy B, Vallyathan V, Landsittel DP, Simenova P, Luster MI (2002) Cytokine polymorphisms in silicosis and other pneumoconioses. Mol Cell Biochem 234–235:219–224
Cappiello F, Barili M, Masciocchi M et al (2005) IL1-group gene polymorphisms and lung function in Italian scleroderma patients. Tissue Antigens 66:S396 (Suppl)
Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–90
McDowell TL, Symons JA, Ploski R, Forre O, Duff GW (1995) A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1 alpha polymorphism. Arthritis Rheum 38:221–228
Wells AU, Hansell DM, Rubens MB, King AD, Cramer D, Black CM et al (1997) Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum 40:1229–1236
Hulkkonen J, Laippala P, Hurme M (2000) A rare allele combination of the interleukin-1 gene complex is associated with high interleukin-1 beta plasma levels in healthy individuals. Eur Cytokine Netw 11:251–255
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Beretta, L., Cappiello, F., Barili, M. et al. T-889C IL-1α promoter polymorphism influences the response to oral cyclophosphamide in scleroderma patients with alveolitis. Clin Rheumatol 26, 88–91 (2007). https://doi.org/10.1007/s10067-006-0308-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-006-0308-0